Tonix Pharmaceuticals Holding (TNXP) Gross Margin (2023 - 2026)

Tonix Pharmaceuticals Holding has reported Gross Margin for 4 years, with the latest figure at 94.81% in Q2 2026.

• On a quarterly basis, Gross Margin rose 15857.0% year-over-year to 94.81% in Q2 2026; TTM through Jun 2026 was 83.83%, a 5455.0% increase from a year earlier, with the FY2025 full-year figure at 49.34%, up 2627.0% from the prior year.
• Gross Margin was 94.81% for Q2 2026 at Tonix Pharmaceuticals Holding, up from 77.06% in the prior quarter.
• The five-year high for Gross Margin was 94.81% in Q2 2026, with the low at 63.76% in Q2 2025.
• Average Gross Margin over 4 years is 38.8%, with a median of 49.54% recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Gross Margin sank 1127 bps in 2025, then jumped 15857 bps in 2026.
• Over 4 years, Gross Margin stood at 37.36% in 2023, then jumped by 45 bps to 54.18% in 2024, then surged by 48 bps to 80.37% in 2025, then gained by 18 bps to 94.81% in 2026.
• The last three Gross Margin figures came in at 94.81% (Q2 2026), 77.06% (Q1 2026), and 80.37% (Q4 2025), per Business Quant data.